5-Hydroxylansoprazole | CAS#131926-98-2 |

5-Hydroxylansoprazole
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 591362

CAS#: 131926-98-2

Description: 5-Hydroxylansoprazole is a metabolite of Lansoprazole, as gastric pump inhibitor

Chemical Structure

5-Hydroxylansoprazole

CAS# 131926-98-2

Instruction

Theoretical Analysis

MedKoo Cat#: 591362
Name: 5-Hydroxylansoprazole
CAS#: 131926-98-2
Chemical Formula: C16H14F3N3O3S
Exact Mass: 385.07
Molecular Weight: 385.360
Elemental Analysis: C, 49.87; H, 3.66; F, 14.79; N, 10.90; O, 12.46; S, 8.32

Price and Availability

Size	Price	Availability
5mg	USD 350	2 Weeks
10mg	USD 600	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: 5-Hydroxylansoprazole; AG-1908;AG 1908; AG1908

IUPAC/Chemical Name: 1H-Benzimidazol-6-ol, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-

InChi Key: IDCLTMRSSAXUNY-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H14F3N3O3S/c1-9-13(20-5-4-14(9)25-8-16(17,18)19)7-26(24)15-21-11-3-2-10(23)6-12(11)22-15/h2-6,23H,7-8H2,1H3,(H,21,22)

SMILES Code: OC1=CC=C2N=C(S(CC3=NC=CC(OCC(F)(F)F)=C3C)=O)NC2=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 385.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Goktas MT, Karaca RO, Kalkisim S, Cevik L, Kilic L, Akdogan A, Babaoglu MO, Bozkurt A, Bertilsson L, Yasar U. Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behçet's Disease. Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):266-271. doi: 10.1111/bcpt.12710. PubMed PMID: 27875029.

2: Zhang D, Zhang Y, Liu M, Wang X, Yang M, Han J, Liu H. Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2013 Sep;38(3):209-15. doi: 10.1007/s13318-012-0115-8. Epub 2012 Dec 11. PubMed PMID: 23229306.

3: Gumus E, Karaca O, Babaoglu MO, Baysoy G, Balamtekin N, Demir H, Uslu N, Bozkurt A, Yuce A, Yasar U. Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol. 2012 May;68(5):629-36. doi: 10.1007/s00228-011-1151-z. Epub 2011 Nov 11. PubMed PMID: 22076562.

4: Zhang D, Wang X, Yang M, Wang G, Liu H. Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects. Xenobiotica. 2011 Jun;41(6):511-7. doi: 10.3109/00498254.2011.559556. Epub 2011 Apr 27. Erratum in: Xenobiotica. 2011 Sep;41(9):836. PubMed PMID: 21521077.

5: Xu HR, Chen WL, Li XN, Chu NN. The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects. Pharm Biol. 2010 Aug;48(8):947-52. doi: 10.3109/13880200903300220. PubMed PMID: 20673183.

6: Song M, Gao X, Hang T, Wen A. Simultaneous determination of lansoprazole and its metabolites 5'-hydroxy lansoprazole and lansoprazole sulphone in human plasma by LC-MS/MS: application to a pharmacokinetic study in healthy volunteers. J Pharm Biomed Anal. 2008 Dec 1;48(4):1181-6. doi: 10.1016/j.jpba.2008.08.034. Epub 2008 Sep 9. PubMed PMID: 18945568.

7: Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T. Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes. J Clin Pharmacol. 2005 Jun;45(6):690-4. PubMed PMID: 15901751.

8: Saito M, Yasui-Furukori N, Uno T, Takahata T, Sugawara K, Munakata A, Tateishi T. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005 Mar;59(3):302-9. PubMed PMID: 15752376; PubMed Central PMCID: PMC1884793.

9: Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T. Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 25;816(1-2):309-14. PubMed PMID: 15664363.

10: Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004 Nov;44(11):1223-9. PubMed PMID: 15496639.

11: Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol. 2004 Nov;60(9):623-8. Epub 2004 Sep 23. PubMed PMID: 15448955.

12: Miura M, Tada H, Suzuki T. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 May 25;804(2):389-95. PubMed PMID: 15081934.

13: Ushiama H, Echizen H, Nachi S, Ohnishi A. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clin Pharmacol Ther. 2002 Jul;72(1):33-43. PubMed PMID: 12152002.

14: Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. Eur J Clin Pharmacol. 2001 Dec;57(10):709-15. PubMed PMID: 11829200.

15: Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M. High-performance liquid chromatographic assay for the simultaneous determination of lansoprazole enantiomers and metabolites in human liver microsomes. J Chromatogr B Biomed Sci Appl. 2001 Jun 5;757(1):127-33. PubMed PMID: 11419737.

16: Masa K, Hamada A, Arimori K, Fujii J, Nakano M. Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs. Biol Pharm Bull. 2001 Mar;24(3):274-7. PubMed PMID: 11256484.

17: Masa K, Arimori K, Nakayama T, Miyamoto S, Fujii J, Nakano M. Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs. Biol Pharm Bull. 1999 May;22(5):504-9. PubMed PMID: 10375172.

18: Arimori K, Yasuda K, Katsuki H, Nakano M. Pharmacokinetic differences between lansoprazole enantiomers in rats. J Pharm Pharmacol. 1998 Nov;50(11):1241-5. PubMed PMID: 9877309.

19: Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16. PubMed PMID: 8627562.

Your view history

5-Hydroxylansoprazole featured